Given the frequent activation of the PI3K-AKT pathway in cancer and its significant upregulation by PARP inhibitors in TNBC, as shown in Figure 3B, the specific role of NPC1L1 in this activation process warrants further investigation. This evidence concerns the gene AKT1 and cancer.